# EFFICACIOUS SKELETAL IMAGING RADIOPHARMACEUTICALS

> **NIH NIH R01** · UNIVERSITY OF CINCINNATI · 1989 · $282,961

## Abstract

High-performance liquid chromatographic (HPLC) analysis has shown that
99mTc-diphosphonate skeletal imaging agents are not pure chemical species,
but rather are complicated mixtures of technetium-diphosphonate complexes.
The focus of this project is the determination of exactly which isolated
metal-diphosphonate complexes are the most effective agents for both
diagnostic and therapeutic nuclear medicine applications.  This will be
accomplished through research bridging the disciplines of inorganic
chemistry, analytical chemistry, radiology, nuclear medicine, and
medicine.  Preparative conditions used to generate metal-diphosphonate
imaging agents will be varied in order to favor the production of specific
metal-diphosphonate complexes, and then HPLC will be used to isolate these
component complexes.  These HPLC isolated components will be evaluated in
animal models for (a) uptake on normal bone relative to uptake in soft
tissues, and (b) uptake on abnormal bone (trauma-induced osteogenesis
model) relative to uptake on normal bone.  Those isolated
metal-diphosphonate complexes containing 99m-Tc or 186-RE which appear most
effective in animal models will be evaluated as diagnostic agents in human
patients with established metastatic disease to bone.  "Instant kit"
formulations will be developed in which the yields of the optimum
99mTc-diphosphonate diagnostic agents are maximized.  The total therapeutic
dose that could be delivered to a metastatic bone cancer site by an
isolated metal-diphosphonate complex containing 186-Re, 32-P or 33-P will
be estimated by external, conjugate view, counting of patients who have
received diagnostic doses of isolated components, and by thermoluminescent
dosimetry in animal models.  Those components with appropriate
scintigraphic and dosimetric properties will be evaluated as palliative
therapeutic agents in human patients suffering from metastatic disease to
the bone that is not-responsive to conventional therapy.

## Key facts

- **NIH application ID:** 3170731
- **Project number:** 5R01CA032863-10
- **Recipient organization:** UNIVERSITY OF CINCINNATI
- **SAM.gov UEI:** DZ4YCZ3QSPR5
- **Principal Investigator:** HARRY R MAXON
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1989
- **Award amount:** $282,961
- **Award type:** 5
- **Project period:** 1980-04-01 → 1992-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3170731

## Citation

> US National Institutes of Health, RePORTER application 3170731, EFFICACIOUS SKELETAL IMAGING RADIOPHARMACEUTICALS (5R01CA032863-10). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3170731. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*